Decoding the functional Fes kinase signaling network topology in a lymphocyte model

The c-Fes protein tyrosine kinase is a proto-oncogene that can also act as a tumor suppressor. We implemented a novel phosphoproteomics-based analysis that establishes cognate kinase-substrate associations, and revealed that c-Fes directly phosphorylates Dok1, Ptpn18 and Sts1, facilitating recruitment of the Src inhibitory kinase Csk to these substrates. These interactions resulted in modulation of Src signaling following B-cell receptor (BCR) stimulation and subsequent alteration of the protein levels of CD19, a membrane-localized BCR co-receptor and emerging key protein affecting the development of B- and plasma cell-lymphoma. Strikingly, manipulating c-Fes expression levels drove opposing biological outcomes. Low-level exogenous c-Fes expression led to a strong increase in CD19 protein levels while high c-Fes expression abolished CD19 protein levels. Thus, we propose that a balance of c-Fes and Src signaling can regulate receptor maintenance, which may influence cellular outcome such as tumorigenesis or tumor suppression.

[1]  J. Brognard,et al.  Orange is the new black: Kinases are the new master regulators of tumor suppression , 2018, IUBMB life.

[2]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[3]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[4]  P. Beltrão,et al.  Reconstructing phosphorylation signalling networks from quantitative phosphoproteomic data , 2018, Essays in biochemistry.

[5]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[6]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[7]  Jared L. Johnson,et al.  EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src , 2015, Nature Structural &Molecular Biology.

[8]  Tony Pawson,et al.  SELPHI: correlation-based identification of kinase-associated networks from global phospho-proteomics data sets , 2015, Nucleic Acids Res..

[9]  A. Reményi,et al.  Structural assembly of the signaling competent ERK2–RSK1 heterodimeric protein kinase complex , 2015, Proceedings of the National Academy of Sciences.

[10]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[11]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[12]  A. Elfiky,et al.  The role of Src in colon cancer and its therapeutic implications. , 2014, Clinical colorectal cancer.

[13]  Melissa J. Landrum,et al.  RefSeq: an update on mammalian reference sequences , 2013, Nucleic Acids Res..

[14]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[15]  Guomin Liu,et al.  Analyzing Protein‐Protein Interactions from Affinity Purification‐Mass Spectrometry Data with SAINT , 2012, Current protocols in bioinformatics.

[16]  S. Knapp,et al.  Small-molecule inhibitors of the c-Fes protein-tyrosine kinase. , 2012, Chemistry & biology.

[17]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[18]  L. del Vecchio,et al.  The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. , 2012, American journal of clinical pathology.

[19]  Tony Pawson,et al.  OpenFreezer: a reagent information management software system , 2011, Nature Methods.

[20]  T. Pawson,et al.  Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor , 2011, Nature Biotechnology.

[21]  P. L. Bergsagel,et al.  Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. , 2010, Blood.

[22]  P. Dubreuil,et al.  FES kinases are required for oncogenic FLT3 signaling , 2010, Leukemia.

[23]  N. Schork,et al.  Kinase mutations in human disease: interpreting genotype–phenotype relationships , 2010, Nature Reviews Genetics.

[24]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[25]  Jeroen Krijgsveld,et al.  Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. , 2009, Analytical chemistry.

[26]  Reinout Raijmakers,et al.  Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics , 2009, Nature Protocols.

[27]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[28]  Z. Jia,et al.  Contributions of F-BAR and SH2 Domains of Fes Protein Tyrosine Kinase for Coupling to the FcεRI Pathway in Mast Cells , 2008, Molecular and Cellular Biology.

[29]  G. Superti-Furga,et al.  Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation , 2008, Cell.

[30]  M. Terol,et al.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Pawson,et al.  Analysis of EphA4 receptor tyrosine kinase substrate specificity using peptide‐based arrays , 2008, The FEBS journal.

[32]  Tony Pawson,et al.  Defining the Specificity Space of the Human Src Homology 2 Domain*S , 2008, Molecular & Cellular Proteomics.

[33]  V. Tybulewicz,et al.  CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand , 2008, Nature Immunology.

[34]  Sebastian A. Wagner,et al.  Suppressor of T‐cell receptor signalling 1 and 2 differentially regulate endocytosis and signalling of receptor tyrosine kinases , 2007, FEBS letters.

[35]  A. DeFranco,et al.  Lipid rafts and B cell signaling. , 2007, Seminars in cell & developmental biology.

[36]  N. Nassar,et al.  A phosphatase activity of Sts-1 contributes to the suppression of TCR signaling. , 2007, Molecular cell.

[37]  Shiro Suetsugu,et al.  Coordination between the actin cytoskeleton and membrane deformation by a novel membrane tubulation domain of PCH proteins is involved in endocytosis , 2006, The Journal of cell biology.

[38]  Yan Gao,et al.  An identity crisis for fps/fes: oncogene or tumor suppressor? , 2005, Cancer research.

[39]  T. Moore,et al.  Human ORFeome version 1.1: a platform for reverse proteomics. , 2004, Genome research.

[40]  C. Heldin,et al.  Suppressors of T-cell Receptor Signaling Sts-1 and Sts-2 Bind to Cbl and Inhibit Endocytosis of Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.

[41]  K. Taskén,et al.  Combined Spatial and Enzymatic Regulation of Csk by cAMP and Protein Kinase A Inhibits T Cell Receptor Signaling* , 2003, The Journal of Biological Chemistry.

[42]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.

[43]  J. Griffin,et al.  Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease , 2002, Oncogene.

[44]  P. Greer.  Closing in on the biological functions of fps/fes and fer , 2002, Nature Reviews Molecular Cell Biology.

[45]  Jynho Kim,et al.  Activated Fes Protein Tyrosine Kinase Induces Terminal Macrophage Differentiation of Myeloid Progenitors (U937 Cells) and Activation of the Transcription Factor PU.1 , 2002, Molecular and Cellular Biology.

[46]  D. Baltimore,et al.  Domain-dependent Function of the rasGAP-binding Protein p62Dok in Cell Signaling* , 2001, The Journal of Biological Chemistry.

[47]  R. Rickert,et al.  CD19-dependent Activation of Akt Kinase in B-lymphocytes* , 2001, The Journal of Biological Chemistry.

[48]  H. Ishikawa,et al.  Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. , 1999, Blood.

[49]  D. Longo,et al.  The protein product of the proto-oncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgM-stimulated human B-lymphoma cells. , 1996, Blood.

[50]  A. Carè,et al.  c-fes expression in ontogenetic development and hematopoietic differentiation. , 1994, Oncogene.

[51]  M. Moran,et al.  The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function , 1989, Molecular and cellular biology.

[52]  T. Pawson,et al.  A conserved domain regulates interactions of the v-fps protein-tyrosine kinase with the host cell. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T Pawson,et al.  A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps , 1986, Molecular and cellular biology.

[54]  T. Pawson,et al.  Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein , 1985, Molecular and cellular biology.

[55]  T. Pawson,et al.  Localization and characterization of phosphorylation sites of the fujinami avian sarcoma virus and prcii virus transforming proteins , 1982, Journal of cellular biochemistry.